GlassScriptPhysician profile
Cathleen E Worthington
NPI 1134842081
$2,665.21
in general payments reported to CMS, 2019-2025
24 companies · $756 in 2025
The $756 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $721 · 2024: $1,188 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.06 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.28 | 2023-2025 | |
| Amgen INC. | $417.26 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $299.88 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $188.50 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $187.79 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $187.18 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.75 | 2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.22 | 2023-2024 | Xifaxan |
| Pfizer INC. | $101.86 | 2023-2025 | |
| Glaxosmithkline, LLC. | $89.54 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $89.53 | 2023-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $44.70 | 2025 | |
| Lundbeck LLC | $34.66 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $33.02 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.85 | 2024 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $32.31 | 2024-2025 | Fanapt |
| Astellas Pharma US INC | $31.81 | 2023-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $30.32 | 2024-2025 | Zoryve |
| Currax Pharmaceuticals LLC | $26.90 | 2023-2025 | Contrave |
| Phadia US INC. | $21.20 | 2025 | Immunocap |
| Exact Sciences Corporation | $18.29 | 2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $17.48 | 2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $17.15 | 2023 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $14.73 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathleen Worthington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.